hERG screening is like a safety check for new medicines. When scientists are creating drugs, they need to make sure these drugs won't cause harm to the heart. hERG screening is a crucial part of this process. It checks if the drugs can block special channels in the heart called hERG potassium channels. These channels control how the heart's electricity works. If these channels are blocked, it can lead to a serious condition called long QT syndrome (LQTS). This condition can cause problems with the heart's rhythm and even lead to sudden cardiac death. So, hERG screening is like a protector, making sure new drugs won't cause harm to our hearts.
Now, the global hERG screening market is divided into different parts based on the type of channels it checks. The voltage-gated ion channel is one type, and it was the biggest in 2021. It's like the most common way to check these channels. Another type is the ligand-gated ion channel, and it's growing the fastest. It's like a newer and faster way to do the screening, making sure it's even better.
There are also different categories based on how the drugs are used. Some are for treating heart rhythm problems (antiarrhythmic), and this was the biggest category in 2021. Another category is for medicines that help with mental health (antipsychotic), and this is growing the fastest. It's like the use of these screenings is expanding to check different types of medicines, making sure they are all safe for our hearts.
In simple terms, hERG screening is like a superhero that checks if new medicines are safe for our hearts. The market for hERG screening is split into different parts based on the type of channels and the kind of medicines it checks. This helps scientists and doctors make sure that all sorts of medicines we use are safe and won't harm our hearts. As technology improves, these screenings get even better, making sure our hearts stay healthy when we take new medicines.
Report Attribute/Metric | Details |
---|---|
Market Size Value In 2022 | USD 0.9 Billion |
Market Size Value In 2023 | USD 1.0 Billion |
Growth Rate | 12.50% (2023-2032) |
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
As heart disease prevalence and the number of heart condition patients both rise, the market is expected to grow. The market is growing as a result of increased R&D activities in support of new product releases. Additionally, it is projected that a rise in the number of innovative drug entity approvals will support the market's growth. The market is growing as a result of both the creation of remedies for illnesses and disorders and the rise in demand for drug formulations. Growing challenges in producing biotechnological or pharmaceutical goods based on the application are also creating more opportunities for the growth of the HERG screening market.
Due to the growth in instances of cardiotoxicity, there has been a significant demand for screening the materials used in pharmaceutical production. Traditional testing methods may not always be better than HERG tests, but they may be safer and more successful when used on medications. Cardiovascular drugs are increasingly having adverse side effects in patients with pre-existing heart conditions. Cardiotoxicity is more common in patients who have had cancer treatment or cardiac surgery. Consequently, there is a rising demand for equipment and services that enable efficient cardiotoxicity testing. The heart has a harder time carrying out normal functions and distributing blood throughout the body when there is cardiotoxicity. Cardiotoxicity consequently increases the risk of cardiomyopathy, which reduces the heart's capacity to pump blood.
Heart disease is the top cause of death for both men and women worldwide. According to the American College of Cardiology, an American will experience a myocardial infarction every 40 seconds. Emergency medical services reported that 356,461 Americans had cardiac arrest outside of a hospital in 2017, and in 52% of those cases, emergency medical services treatment was started. Only 18.7% of the patients had ventricular fibrillation or ventricular tachycardia at the start of their treatment, which might have been shocked by an AED. 10.4% of adults survived after leaving the hospital, and 8.4% of them had satisfactory functional status.
Sedentary habits and common risk factors, such as hypertension (which can range from 28% in the United Arab Emirates to 41% in Libya and Morocco), diabetes (which can range from 4% in the Islamic Republic of Iran to 19% in Sudan), and hypercholesterolemia (which can range from 14% in Lebanon to 52% in the Islamic Republic of Iran), are to blame for the prevalence of cardiovascular diseases. The market for drug discovery will expand as a result of the rise in heart disease, boosting the expansion of the HERG screening industry.Thus, driving the HERG Screening market revenue.
The HERG Screening market segmentation, based on Type, includes Gene KCNH2 and Mutant KCNH2. Gene KCNH2 segment dominated the market in 2022. This channel is especially important for the generation and transmission of electrical impulses as it is in charge of removing positively charged potassium atoms from the cells. This is so that it can move the atoms of potassium. The KCNH2 gene is in charge of controlling and supplying the necessary instructions for the production of potassium channels. The main reason causing the ultimate emergence of cardiac arrhythmia was the KCNH2 mutation.
The HERG Screening market segmentation, based on Ion Channel, includes Voltage Gated and Ligand Gated. Voltage Gated segment dominated the HERG Screening market in 2022.The members of the voltage-gated ion channel family that regulate the open and closed states of the cell membrane potential include Na+, Ca+, and K+. The ionic gradients required for regular cell activity are maintained by these channels in a variety of cell types, including neurons, heart muscle, and skeletal muscle. The movement of ions across cell membranes is tightly regulated by these channels.
The HERG Screening market segmentation, based on Application, includes Antiarrhythmic, Antipsychotic, Antibiotics, and Others. Antiarrhythmic segment dominated the market in 2022. Antiarrhythmic medications are used to treat symptomatic tachycardias and premature beats. These can be administered intravenously in an emergency or orally for long-term treatment. These drugs either prevent aberrant pacemaker tissue firing or reduce the speed at which impulses are transmitted in tissues that conduct too quickly or engage in reentry. The use of these assays for arrhythmia treatment, scientific investigations into the safety and effectiveness of HERG screening, and an increase in cardiovascular diseases globally are all factors propelling the market's growth.
Figure 1: HERG Screening Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America HERG Screening Market dominated this market in 2022 (45.80%). Every 40 seconds, a citizen of the United States will experience a myocardial infarction, according to the American College of Cardiology. In 2017, 356,460 Americans went through an out-of-hospital cardiac arrest, and in 52% of those cases, emergency medical services were called.Further, the U.S. HERG Screening market held the largest market share, and the Canada HERG Screening market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: HERG Screening Market Share By Region 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe HERG Screening market accounted for the healthy market share in 2022. Europe's western and eastern regions make up the majority of the market for HERG screening and are both regarded as major contributors.Further, the German HERG Screening market held the largest market share, and the U.K HERG Screening market was the fastest growing market in the European region.
The Asia Pacific HERG Screening market is expected to register significant growth from 2024 to 2032. A significant portion of the people in the area have chronic heart conditions, and the incidence of inflammatory disorders is rising quickly as well. Moreover, China’s HERG Screening market held the largest market share, and the Indian HERG Screening market was the fastest growing market in the Asia-Pacific region.
HERG Screening Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the HERG Screening market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, HERG Screening Industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the HERG Screening Industry to benefit clients and increase the market sector. In recent years, the HERG Screening Industry has offered some of the most significant advantages to medicine. Major players in the HERG Screening market, including Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, and Aurora Biomed, are attempting to increase market demand by investing in research and development operations.
Charles River Laboratories International Inc. (Charles River), a contract research organisation (CRO), provides essential products and services to speed up analysis, medication discovery, and development. It offers a variety of services for fundamental research, drug discovery, and safety assessment. The company also offers assistance with production, operations, and employment. It provides treatments for conditions affecting the cardiovascular, nervous, metabolic, inflammatory, pulmonary, musculoskeletal, and oncological systems. Charles River provides services to prestigious hospitals, universities, government agencies, pharmaceutical and biotechnology companies, and other clientele. The headquarters of Charles River are located in Wilmington, Massachusetts, a city in the US.
Analytical testing services are provided to clients in a variety of industries by a life sciences company called Eurofins Scientific SE (Eurofins). The company offers a variety of services including forensics, environmental testing, agroscience, biopharma, pharmaceutical discovery, early development, pharmaceutical central laboratory, biopharma product testing, and product testing. Its analytical methods help in figuring out whether biological products and chemicals are pure, real, and safe. It draws on its knowledge in logistics and information technology to offer a range of services. The company has activities in North America, South America, the Middle East, Asia Pacific, and Europe. Eurofins' main office is in Luxembourg. In July 2017, Eurofins Scientific purchased Discover X, a market leader in drug discovery technologies and services from target identification and lead discovery to preclinical and beyond.
Key Companies in the HERG Screening market include
HERG Screening Industry Developments
March 2020: An alliance was formed between Charles River Laboratories and Deciphex, a pioneer in preclinical digital pathology software-as-a-service. The organisations will collaborate to co-develop deep learning-enabled technologies to facilitate expedited pathology analytics, and Charles River will serve as the sole contract research organisation providing the Patholytix preclinical solution to clients.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)